SynthesisBritish journal of clinical pharmacology2017
Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.
Synthesis in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Cardiovascular Disorders and Falls Among Older Adults: A Systematic Review and Meta-Analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Pooled it
- Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.British journal of clinical pharmacology · 2017Pooled it
- Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort.NPJ Parkinson's disease · 2025Article
- Cardiovascular Pharmacotherapy and Falls in Old People: Risks and Prevention-An Observational Case-Control Study.Journal of clinical medicine · 2025Article
- Preadmission medications and recent falls in older inpatients: an observational study.International journal of clinical pharmacy · 2025Observational
- Cholinesterase Inhibitor Initiation Does Not Increase the Risk of Fall-Related Injury in Older Adults Treated With Beta-Blockers: A Self-Controlled Case Series Design.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Fall risk factors among poly-medicated older Lebanese patients in primary care settings: a secondary cross-sectional analysis of the "MGPIDP-L project".BMC geriatrics · 2024Article
- The role of plasma concentrations and drug characteristics of beta-blockers in fall risk of older persons.Pharmacology research & perspectives · 2023Article
- Chronic kidney disease and polypharmacy as risk factors for recurrent falls in a nursing home population.Health science reports · 2023Article
- The development, incidence and treatment trends of trochanteric fractures in Germany: a cohort study.Journal of orthopaedic surgery and research · 2023Article
- Drug Utilisation Review among Geriatric Patients with Noncommunicable Diseases in a Primary Care Setting in Malaysia.Healthcare (Basel, Switzerland) · 2023Article
- Variation in Mean Arterial Pressure Increases Falls Risk in Elderly Physically Frail and Prefrail Individuals Treated With Antihypertensive Medication.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Article
- Article
- Predictors of poor medication adherence of older people with hypertension.Nursing open · 2022Article
- Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction.The American journal of medicine · 2021Observational
- Neuropsychiatric Consequences of Lipophilic Beta-Blockers.Medicina (Kaunas, Lithuania) · 2021Review
- Objectives, design and main findings until 2020 from the Rotterdam Study.European journal of epidemiology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the association between use of β-blockers and β-blocker characteristics - selectivity, lipid solubility, intrinsic sympathetic activity (ISA) and CYP2D6 enzyme metabolism - and fall risk.
methodsData from two prospective studies were used, including community-dwelling individuals, n = 7662 (the Rotterdam Study) and 2407 (B-PROOF), all aged ≥55 years. Fall incidents were recorded prospectively. Time-varying β-blocker use was determined using pharmacy dispensing records. Cox proportional hazard models adjusted for age and sex were applied to determine the association between β-blocker use, their characteristics - selectivity, lipid solubility, ISA and CYP2D6 enzyme metabolism - and fall risk. The results of the studies were combined using meta-analyses.
resultsIn total 2917 participants encountered a fall during a total follow-up time of 89 529 years. Meta-analysis indicated no association between use of any β-blocker, compared to nonuse, and fall risk, hazard ratio (HR) = 0.97 [95% confidence interval (CI) 0.88-1.06]. Use of a selective β-blocker was also not associated with fall risk, HR = 0.92 (95%CI 0.83-1.01). Use of a nonselective β-blocker was associated with an increased fall risk, HR = 1.22 (95%CI 1.01-1.48). Other β-blocker characteristics including lipid solubility and CYP2D6 enzyme metabolism were not associated with fall risk.
conclusionOur study suggests that use of a nonselective β-blocker, contrary to selective β-blockers, is associated with an increased fall risk in an older population. In clinical practice, β-blockers have been shown effective for a variety of cardiovascular indications. However, fall risk should be considered when prescribing a β-blocker in this age group, and the pros and cons for β-blocker classes should be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.